Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,413 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Laboratory testing Clear all
Active, not recruiting Phase 2 Interventional

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

NCT05669664
View directory record Official record
Conditions
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darolutamide, Leuprolide Acetate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Irvine, California • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Recruiting Phase 2 Interventional

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

NCT05333458
View directory record Official record
Conditions
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Selinexor
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Hartford, Connecticut • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Completed Not applicable Interventional

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

NCT00363012
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method, biopsy, Sterile water placement
Biological · Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 27, 2026, 1:02 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Understanding the Long-term Impact of COVID on Children and Families

NCT05172011
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 25 Years
Enrollment
15,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
65
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 27, 2026, 1:02 PM EDT
Completed No phase listed Observational

Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy

NCT02724319
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
SpartanRX
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 27, 2026, 1:02 PM EDT
Suspended Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Costa Mesa, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

NCT04548752
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
533
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer

NCT03103321
View directory record Official record
Conditions
Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage I Prostate Cancer, PSA Level Five to Ten, PSA Level Less Than Five, PSA Level Ten to Fifty
Interventions
Internet-Based Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration, Laboratory Biomarker Analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
28
States / cities
Bellflower, California • Los Angeles, California • Oakland, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 27, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Results available

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

NCT01206465
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pralatrexate, fluorouracil, laboratory biomarker analysis, DNA analysis, high performance liquid chromatography, polymerase chain reaction, nucleic acid sequencing, pharmacological study, pharmacogenomic studies, polymorphism analysis
Drug · Other · Genetic
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 27, 2026, 1:02 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

NCT03816358
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of Novel Point of Care Coagulation System in Pregnant Women

NCT04301193
View directory record Official record
Conditions
Hemorrhage, Coagulation Delay
Interventions
Quantra Analyzer
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 27, 2026, 1:02 PM EDT
Completed Not applicable Interventional Results available

Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)

NCT02074384
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous Glucose Monitor, Self Monitoring Blood Glucose, Clinician
Device · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
7 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
New Haven, Connecticut • Tallahassee, Florida • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 27, 2026, 1:02 PM EDT
Terminated No phase listed Observational

Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

NCT00918658
View directory record Official record
Conditions
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
biologic sample preservation procedure, immunologic technique, laboratory biomarker analysis
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 27, 2026, 1:02 PM EDT
Recruiting No phase listed Observational

Endometriosis Pain

NCT06101303
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Psychophysical assessment, Psychophysical assessments of experimental pain, Blood, urine and saliva samples, Biopsy and surgery-related data.
Other · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Recruiting No phase listed Observational

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

NCT04794322
View directory record Official record
Conditions
Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Fallopian Tube Neoplasms, High Grade Ovarian Serous Adenocarcinoma, Stage I Ovarian Cancer, Stage II Ovarian Cancer, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions
Uterine lavage, or a wash of the womb, Blood sample, Pap smear
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
6
States / cities
Little Rock, Arkansas • San Francisco, California • Annapolis, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 27, 2026, 1:02 PM EDT
Completed Not applicable Interventional Results available

Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease

NCT03383627
View directory record Official record
Conditions
Diabetes, Kidney Diseases
Interventions
Continuous Glucose Monitoring
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 27, 2026, 1:02 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Vaccination on Th2 Immunity in Infancy

NCT02213341
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Skin prick allergen test, Blood draw
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Months to 7 Months
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 27, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

NCT01433705
View directory record Official record
Conditions
Heart Disease
Interventions
Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 27, 2026, 1:02 PM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in African Americans

NCT05591131
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Peritoneal Cancer
Interventions
genetic testing, Survey Administration
Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 27, 2026, 1:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Cerebral Blood Flow and Childhood Obstructive Sleep Apnea

NCT02995837
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome
Interventions
Sleep Study, Neurocognitive Testing, CBF During Wakefulness, CBF During Sleep
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 12 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 27, 2026, 1:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

NCT07526545
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy Procedure, Diagnostic Procedure, Electronic Health Record Review, Magnetic Resonance Imaging
Procedure · Device · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Recruiting Phase 2 Interventional

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NCT05408845
View directory record Official record
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
154
States / cities
Birmingham, Alabama • Duarte, California • Dublin, California + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

NCT05985681
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV16 RG1 VLP Vaccine, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 1:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Lifestyle Change Via Tailored mHealth Feedback to Improve Health

NCT03367936
View directory record Official record
Conditions
Overweight and Obesity
Interventions
One-on-one Session, Self-monitoring, Feedback
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 27, 2026, 1:02 PM EDT